RxDoctor Payments Data

Robert Werner, MD

Ophthalmology · Cincinnati, OHNPI 1487656633

Payments from drug & device makers

$1,707in general payments, 2019–2025

Across 84 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$425
  • Sun Pharmaceutical Industries Inc.$241
  • Amgen$159
  • Aerie Pharmaceuticals, Inc.$111
  • Tarsus Pharmaceuticals, Inc.$92
  • Bausch & Lomb Americas Inc.$87
  • plus $593 from 15 others

What the payments were for

  • Food & beverage$1,707100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,707 in reported general payments places this provider in the 55th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$94,175
Medicare patients
485
Services billed
1,098

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine57$73,959
LumiganBimatoprost47$21,454
RocklatanNetarsudil Mesylat/Latanoprost17$13,602
RhopressaNetarsudil Mesylate21$8,602
CombiganBrimonidine Tartrate/Timolol16$6,664
Cyclosporine11$5,942
VyzultaLatanoprostene Bunod13$4,202
SimbrinzaBrinzolamide/Brimonidine Tart11$3,835
Brimonidine Tartrate27$2,643
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat131$1,884
Latanoprost156$1,218
Prednisolone Acetate29$1,181
Tobramycin-DexamethasoneTobramycin/Dexamethasone22$987
Timolol Maleate62$561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$425$102,076120 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$111$22,20438 claims
Bausch & Lomb Americas Inc.Vyzulta$87$4,20213 claims
AlconSimbrinza$67$3,83511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →